Scala Biodesign Secures $16M to Advance AI Drug Discovery
Scala Biodesign announced a $16 million Series A financing to accelerate its AI-driven protein engineering platform. The round was led by Grove Ventures with participation from TLV Partners, Deep Insight and support from the Israel Innovation Authority. Built on research from the Weizmann Institute of Science, Scala aims to make protein design faster and more predictable, helping developers bring new biologics and therapeutic proteins to patients sooner.
AI Revolutionizes Protein Design for Faster Therapies
Traditional protein-based drug development often relies on time-consuming cycles of lab experiments and trial-and-error optimization, which can take years and cost hundreds of millions. Scala applies computational models and machine learning to predict protein stability, folding and binding properties, reducing the need for exhaustive wet-lab screening. By focusing on sequence-to-function prediction and targeted modifications, the platform increases the likelihood that candidate proteins will perform as intended before they enter costly experimental stages.
Accelerating Pharmaceutical Innovation and Patient Outcomes
Pharmaceutical companies are already testing Scala’s platform in real programs. For example, Boehringer Ingelheim has used Scala’s tools to improve lead candidates, illustrating how AI can be integrated into existing R&D workflows. The new funding will support further model development, expansion of partnerships and scaling of computational infrastructure. For investors, scientists and healthcare leaders, Scala represents a practical example of how AI can shorten timelines, lower development costs and expand the range of viable biologic therapies available to patients.
As AI models grow more accurate and compute becomes more accessible, platforms like Scala’s may shift protein engineering from an artisanal process to a repeatable pipeline, enabling faster translation of biological insight into medicines that reach patients more quickly.
